 |
|
Potential Alzheimer's disease drug target identified by UC San Diego researcher
March 17, 2008In findings with the potential to provide a therapy for Alzheimer's disease patients where none now exist, a researcher at the University of California, San Diego and colleagues have demonstrated in mice a way to reduce the overproduction of a peptide associated with the disease. The study, which showed substantial improvement in memory in an animal model of Alzheimer's disease, was led by Vivian Y. H. Hook, Ph.D., professor of the Skaggs School of Pharmacy and Pharmaceutical Sciences and professor of neurosciences, pharmacology and medicine at the UCSD School of Medicine, together with American Life Science Pharmaceuticals of San Diego. The study will be published in the March 21 edition of the Journal of Biological Chemistry, online March 14.
A hallmark sign of Alzheimer's disease, seen during autopsy of a patient's brain, is the accumulation of amyloid plaque deposits composed primarily of the neurotoxic beta-amyloid (Aβ) peptide which is believed to be a major factor in the cause of the disease. The Aβ peptides are "cut" out from a larger protein called the amyloid precursor protein (APP) and bind together to form plaques in brain regions responsible for memory. One drug strategy to fight Alzheimer's disease is to reduce production of Aβ.
"We discovered two chemical compounds that inhibit a new enzyme target, leading to reduced production of beta-amyloid and improved memory in a mouse model of Alzheimer's disease," said Hook.
Accumulation of Aß and plaque build-up are initiated when the large precursor protein, APP, a long string of amino acids, is "cut" into the smaller, neurotoxic Aβ peptides that generate amyloid plaques. Protease enzymes, a type of protein, are the "scissors" that cut the large APP to generate Aβ peptides. The protease must cut the APP amino acid sequence in two places: at the beta-secretase and the gamma-secretase sites. In this study, by inhibiting and therefore preventing the enzymatic "scissors" from "cutting" the APP chain into smaller peptides, the research team observed improved memory, as well as reduced levels of beta-amyloid protein in the brain, in mice bred to exhibit Alzheimer's disease symptoms.
In the past, many scientists have focused on a mutant beta-secretase sequence only seen in one extended family of patients in Sweden with Alzheimer' disease, Hook explained. This mutation, the so-called Swedish mutation, was known to result in an overproduction of Aβ. Past research has shown that this Swedish mutant sequence is cut by a protease called BACE1.
Hook and colleagues found that a different protease, called Cathepsin B (CatB) works to cut the normal beta-secretase site - which is the site present in more than 99 percent of patients with Alzheimer's disease - but not the Swedish mutant site. They also tested compounds that inhibit CatB - E64d and CA074Me -in a mouse model of Alzheimer's disease with the normal beta-secretase site.
"After drug treatment, using water maze memory tests, we found that the mice exhibited great improvement in their memory, as well as reduced brain levels of beta amyloid," said Hook. "These results are consistent with previous research indicating that CatB is elevated in brains of patients with Alzheimer's disease."
She added that a drug that duplicates this reduction by targeting CatB in humans could be an effective treatment for Alzheimer's disease in the more than 99 percent of individuals with the normal beta-secretase site. "By disabling the enzyme's ability to cut the 'beta' end of the amino acid sequence, researchers may discover a way to limit production of neurotoxic Aβ and reduce amyloid plaques in the brain."
University of California - San Diego
Accumulation of Aß and plaque build-up are initiated when the large precursor protein, APP, a long string of amino acids, is "cut" into the smaller, neurotoxic Aβ peptides that generate amyloid plaques. Protease enzymes, a type of protein, are the "scissors" that cut the large APP to generate Aβ peptides. The protease must cut the APP amino acid sequence in two places: at the beta-secretase and the gamma-secretase sites. In this study, by inhibiting and therefore preventing the enzymatic "scissors" from "cutting" the APP chain into smaller peptides, the research team observed improved memory, as well as reduced levels of beta-amyloid protein in the brain, in mice bred to exhibit Alzheimer's disease symptoms.
In the past, many scientists have focused on a mutant beta-secretase sequence only seen in one extended family of patients in Sweden with Alzheimer' disease, Hook explained. This mutation, the so-called Swedish mutation, was known to result in an overproduction of Aβ. Past research has shown that this Swedish mutant sequence is cut by a protease called BACE1.
Hook and colleagues found that a different protease, called Cathepsin B (CatB) works to cut the normal beta-secretase site - which is the site present in more than 99 percent of patients with Alzheimer's disease - but not the Swedish mutant site. They also tested compounds that inhibit CatB - E64d and CA074Me -in a mouse model of Alzheimer's disease with the normal beta-secretase site.
"After drug treatment, using water maze memory tests, we found that the mice exhibited great improvement in their memory, as well as reduced brain levels of beta amyloid," said Hook. "These results are consistent with previous research indicating that CatB is elevated in brains of patients with Alzheimer's disease."
She added that a drug that duplicates this reduction by targeting CatB in humans could be an effective treatment for Alzheimer's disease in the more than 99 percent of individuals with the normal beta-secretase site. "By disabling the enzyme's ability to cut the 'beta' end of the amino acid sequence, researchers may discover a way to limit production of neurotoxic Aβ and reduce amyloid plaques in the brain."
University of California - San Diego
Drug Target Current Events and Drug Target News RSSResearchers discover that SLC2A9 is a high-capacity urate transporter in humans
An international team of researchers led by Professors Mark Caulfield and Patricia Munroe, from the William Harvey Research Institute at Barts and The London School of Medicine and Dentistry with Chris Cheeseman at the University of Alberta in Canada and Kelle Moley at the University of Washington in USA, have shown that the SLC2A9 gene, which encodes a glucose transporter, is also a high-capacity urate transporter, and thus possibly a new drug target for gout.
Groundbreaking Discovery May Lead to Stronger Antibiotics
The last decade has seen a dramatic decline in the effectiveness of antibiotics, resulting in a mounting public health crisis across the world. A new breakthrough by University of Virginia researchers provides physicians and patients a potential new approach toward the creation of less resistant and more effective antibiotics.
Discovery offers new understanding of diabetes drug target
Scientists at the University of Leicester have published findings about a new advance in the study of major diabetes drug target.
Breast cancer treatment resistance linked to signaling pathway
Activation of the Src signaling pathway may cause resistance to standard medical treatment in some patients with breast cancer, and inhibition of this pathway holds the potential to overcome that resistance, according to data presented here at the American Association for Cancer Research Molecular Diagnostics in Cancer Therapeutic Development meeting.
Tuberculosis drug shows promise against latent bacteria
A new study has shown that an investigational drug (R207910, currently in clinical trials against multi-drug resistant tuberculosis strains) is quite effective at killing latent bacteria. This revelation suggests that R207910 may lead to improved and shortened treatments for this globally prevalent disease.
Protein found that regulates gene critical to dopamine-releasing brain cells
Researchers have identified a protein they say appears to be a primary player in maintaining normal functioning of an important class of neurons - those brain cells that produce, excrete and then reabsorb dopamine neurotransmitters.
Atomic structure of the mammalian 'fatty acid factory' determined
Mammalian fatty acid synthase is one of the most complex molecular synthetic machines in human cells. It is also a promising target for the development of anti-cancer and anti-obesity drugs and the treatment of metabolic disorders.
New discoveries from Harvard and Baylor get to the heart of cardiovascular disease
Even if you eat right and exercise regularly, chances are high that you'll still die of a heart attack or stroke. But thanks to new findings by researchers from Harvard and Baylor, the odds may finally shift in your favor.
Failure to bridle inflammation spurs atherosclerosis
When a person develops a sore or a boil, it erupts, drawing to it immune system cells that fight the infection. Then it resolves and flattens into the skin, often leaving behind a mark or a scar.
Unexpected finding of molecule's dual role in mice may open new avenue to cholesterol reduction
Researchers have discovered an unknown regulator of fat and cholesterol production in the liver of mice, a significant finding that could lead to new therapies for lowering unhealthy blood levels of cholesterol and fats.
More Drug Target Current Events and Drug Target News Articles
 | In Silico Technologies in Drug Target Identification and Validation (Drug Discoveries Series) The pharmaceutical industry relies on numerous well-designed experiments involving high-throughput techniques and in silico approaches to analyze potential drug targets. These in silico methods are often predictive, yielding faster and less expensive analyses than traditional in vivo or in vitro procedures. In Silico Technologies in Drug Target Identification and Validation addresses the... |
 | Voltage-Gated Ion Channels as Drug Targets (Methods and Principles in Medicinal Chemistry) Edited by the most prominent person in the field and top researchers at US pharmaceutical companies, this is a unique resource for drug developers and physiologists seeking a molecular-level understanding of ion channel pharmacology. After an introduction to the topic, the authors evaluate the structure and function of ion channels, as well as related drug interaction. A section on assay... |
 | Target Validation in Drug Discovery This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux,... |
 | G Protein-Coupled Receptors as Drug Targets: Analysis of Activation and Constitutive Activity (Methods and Principles in Medicinal Chemistry) With its particular emphasis on the constitutive activity of G-protein-coupled receptors (GPCRs)s, this book comprehensively discusses an important biological process that has not yet been covered in such depth in any other existing books on GPCRs. The international team of highly distinguished authors addresses in detail current models and concepts, to introduce medicinal chemists,... |
 | Industrialization of Drug Discovery: From Target Selection Through Lead Optimization (Drug Discovery) The drug discovery and development process is getting longer, more expensive, and no better. The industry suffers from the same clinical attrition and safety-related market withdrawal rates today as it did 20 years ago. Industrialization of Drug Discovery: From Target Selection Through Lead Optimization scrutinizes these problems in detail, contrasting the promise of technology and... |
 | Bacterial Signal Transduction: Networks and Drug Targets (Advances in Experimental Medicine and Biology) (Advances in Experimental Medicine and Biology) This fascinating book encourages many microbiologists and students to enter the new world of signal transduction in microbiology. Over the past decade, a vast amount of exciting new information on the signal transduction pathway in bacteria has been brought to light. Reports on these developments have been put together in this book, Bacterial Signal Transduction: Networks and Drug Targets. The... |
 | Drug Targets in Kinetoplastid Parasites (Advances in Experimental Medicine and Biology) (Advances in Experimental Medicine and Biology) If viewed globally, the parasitic diseases pose an increasing threat to human health and welfare. The diseases caused by kinetoplastid protozoan parasites like Leishmania and Trypanosoma continue as a cause of suffering for many millions of people in both tropical and subtropical regions of the world. Leishmania species are found throughout Latin America, Africa and Asia. Trypanosoma cruzi that... |
 | Cognitive Enhancing Drugs (Milestones in Drug Therapy) During the past decade research into the pharmacology of cognition, particularly regarding learning and memory, has supported the concept that many potential neural targets exist for the development of cognitive-enhancing drugs. Whereas the main impetus for this research has been the ever growing population of individuals with dementing disorders such as Alzheimer`s disease, attention is also... |
 | Insights into Receptor Function and New Drug Development Targets (Research and Perspectives in Endocrine Interactions) We are now on the verge of viewing effector molecules and other regulatory sites as therapeutic targets for the amelioration of human and animal disease. The recognition, for example, that mutant proteins are frequently misrouted molecules, rather than functionally defective ones, changes our approach to "inborn errors of metabolism" and offers new approaches for pharmacological discovery, based... |
| Enzymes As Targets for Drug Design by Michael G. Palfreyman, Peter P. McCann, Walter Lovenberg, Jose Temple |
| © 2008 BrightSurf.com |